Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Swindells

Showing results (101-110 of 170) with videos related to

Pageof 17
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 18, 2015
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis PreventionAnthony T Podany, Yajing Bao, Susan Swindells, et al.
Brain Communications|July 11, 2022
Signatures of somatosensory cortical dysfunction in Alzheimer's disease and HIV-associated neurocognitive disorderChloe C Casagrande, Alex I Wiesman, Mikki Schantell, et al.
Cerebral Cortex (New York, N.Y. : 1991)|July 20, 2022
Convergent and divergent oscillatory aberrations during visuospatial processing in HIV-related cognitive impairment and Alzheimer's diseaseChloe E Meehan, Christine M Embury, Alex I Wiesman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2011
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267Kelly E Dooley, Jeong-Gun Park, Susan Swindells, et al.
Journal of Clinical Microbiology|January 17, 2014
Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TBAnne F Luetkemeyer, Michelle A Kendall, Xingye Wu, et al.
The Journal of Antimicrobial Chemotherapy|December 25, 2019
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adultsScott L Letendre, Anthony Mills, Debbie Hagins, et al.
The American Journal of Tropical Medicine and Hygiene|August 21, 2023
Preferences of Patients and Providers in High-Burden Malaria Settings for Long-Acting Malaria ChemopreventionKimberly K Scarsi, Harlan Sayles, Kelvin Kapungu, et al.
Journal of the International AIDS Society|January 9, 2020
New opportunities in tuberculosis prevention: implications for people living with HIVLucia González Fernández, Esther C Casas, Satvinder Singh, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2022
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based DosingMichelle M Pham, Anthony T Podany, Noluthando Mwelase, et al.
JAMA|August 15, 2006
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionSusan Swindells, A Gregory DiRienzo, Timothy Wilkin, et al.
Pageof 17

Showing results (101-110 of 170) with videos related to

Sort By:
Pageof 17
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 18, 2015
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis PreventionAnthony T Podany, Yajing Bao, Susan Swindells, et al.
Brain Communications|July 11, 2022
Signatures of somatosensory cortical dysfunction in Alzheimer's disease and HIV-associated neurocognitive disorderChloe C Casagrande, Alex I Wiesman, Mikki Schantell, et al.
Cerebral Cortex (New York, N.Y. : 1991)|July 20, 2022
Convergent and divergent oscillatory aberrations during visuospatial processing in HIV-related cognitive impairment and Alzheimer's diseaseChloe E Meehan, Christine M Embury, Alex I Wiesman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2011
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267Kelly E Dooley, Jeong-Gun Park, Susan Swindells, et al.
Journal of Clinical Microbiology|January 17, 2014
Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TBAnne F Luetkemeyer, Michelle A Kendall, Xingye Wu, et al.
The Journal of Antimicrobial Chemotherapy|December 25, 2019
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adultsScott L Letendre, Anthony Mills, Debbie Hagins, et al.
The American Journal of Tropical Medicine and Hygiene|August 21, 2023
Preferences of Patients and Providers in High-Burden Malaria Settings for Long-Acting Malaria ChemopreventionKimberly K Scarsi, Harlan Sayles, Kelvin Kapungu, et al.
Journal of the International AIDS Society|January 9, 2020
New opportunities in tuberculosis prevention: implications for people living with HIVLucia González Fernández, Esther C Casas, Satvinder Singh, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2022
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based DosingMichelle M Pham, Anthony T Podany, Noluthando Mwelase, et al.
JAMA|August 15, 2006
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionSusan Swindells, A Gregory DiRienzo, Timothy Wilkin, et al.
Pageof 17